Alphamab Oncology 9966
HKEX · Hong Kong SAR China · Health Technology
HKD 8.22-0.23 (-2.72%)
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
NEW YORK, August 04, 2026--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab.
Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative locally advanced or metastatic breast cancer (BC), will be presented as a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The 2026 ASCO Annual Meeting will be held from May 29, 2026 to June 2, 2026 (local time) in Chicag
Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with albumin-bound Docetaxel for Injection (HB1801) from CSPC as neoadjuvant treatment of breast cancer, have been
Recent share performance and business snapshot Alphamab Oncology (SEHK:9966) has drawn fresh attention after a strong run in recent weeks, with the share price showing gains over the past week, month and past 3 months. For investors, this move sits against a backdrop of HK$566.235 million in revenue and a reported net loss of CN¥113.939 million, alongside a market value of about HK$10.88b. See our latest analysis for Alphamab Oncology. The recent 20.49% 7-day share price return and 27.61%...
Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with Docetaxel for Injection (Albumin-bound) (HB1801), has met the pre-specified primary endpoint of total pathological complete response (tpCR) in a Phase III clinical study (KN026-004) f
Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress.
Alphamab Oncology (SEHK:9966) received acceptance of its Investigational New Drug application for JSKN021. JSKN021 is a first in class dual payload EGFR/HER3 bispecific antibody drug conjugate targeting advanced solid tumors. IND acceptance allows Phase I clinical trials to begin, focusing on patients with advanced solid tumors. For investors tracking cancer drug developers, Alphamab Oncology operates in the antibody drug conjugate space, where companies are working to address tumor...
Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical study of JSKN021 for the treatment of advanced malignant solid tumors.
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of HER2-positive advanced colorectal cancer (CRC). JSKN003 is independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK).
Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), were recently published in the top-tier oncology journal Annals of Oncology (IF:65.4). The publicati
Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced or metastatic platinum-resistant recurrent
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.